Akèy › Kansè Endomèt › Distrik Columbia › Washington
Etid klinik pou Kansè Endomèt nan Washington, DC
18 etid pou Kansè Endomèt ap chèche patisipan nan sit nan ak bò kote Washington (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Ap rekriteFaz 3
- MedStar Washington Hospital Center, Washington D.C.
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Ap rekriteFaz 2
- Walter Reed National Military Medical Center, Bethesda · 7 mi lwen
- National Institutes of Health Clinical Center, Bethesda · 7 mi lwen
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
Ap rekriteFaz 2
- National Institutes of Health Clinical Center, Bethesda · 7 mi lwen
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Ap rekriteFaz 1
- Georgetown University Medical Center, Washington D.C.
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
Ap rekriteFaz 3
- MedStar Washington Hospital Center, Washington D.C.
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
Ap rekriteFaz 3
- MedStar Washington Hospital Center ( Site 5005), Washington D.C.
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
Ap rekriteFaz 3
- MedStar Washington Hospital, Washington D.C.
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
Ap rekriteFaz 3
- Research Site, Silver Spring · 7 mi lwen
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
Ap rekriteFaz 1
- Georgetown University Medical Center, Washington D.C.
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Ap rekriteFaz 1/2
- Children's National Medical Center, Washington D.C.
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Ap rekriteFaz 1
- Normunity Investigational Site, Washington D.C.
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1/2
- Johns Hopkins University, Sibley Memorial Hospital, Washington D.C.
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- National Institutes of Health, Bethesda · 7 mi lwen
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
Ap rekriteFaz 3
- Research Site, Washington D.C.
- Research Site, Silver Spring · 7 mi lwen
Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer
Ap rekriteFaz 1/2
- National Institutes of Health Clinical Center, Bethesda · 7 mi lwen
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Silver Spring · 7 mi lwen
- Massive Bio SYNERGY-AI site, Bethesda · 7 mi lwen
BP1001-A in Patients With Advanced or Recurrent Solid Tumors
Ap rekriteFaz 1
- Holy Cross Hospital, Silver Spring · 7 mi lwen
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
Ap rekriteFaz 2/3
- Maryland Oncology Hematology, P.A., Silver Spring · 7 mi lwen
Etid Kansè Endomèt nan lòt vil
- Houston, TX68 etid
- New York City, NY52 etid
- Boston, MA50 etid
- Arlington, VA39 etid
- Nashville, TN38 etid
- Los Angeles, CA34 etid
- St. Louis, MO29 etid
- Philadelphia, PA28 etid
- San Antonio, TX27 etid
- Columbus, OH25 etid
- Oklahoma City, OK25 etid
- Chicago, IL25 etid
Lòt etid nan Washington
- Kansè (tout kalite)58 etid
- Kansè Poumon ki pa ti selil55 etid
- Kansè nan tete46 etid
- Kansè Metastatik43 etid
- Kansè poumon41 etid
- Kansè pwostat38 etid
- Obèsite33 etid
- Kansè kolorektal29 etid
- Maladi kadyovaskilè28 etid
- Kansè vejik26 etid
- Leksemi mieloïd egi24 etid
- Kansè ovè23 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.